donate-now donate-now

A SUPPORTIVE AND CARING VOICE CALL 0800 ECZEMA (329 362)

NSW Residents

 

Trial Title: The effect of immune milk proteins on atopic eczema

 

Brief Overview:

 

The Griffith Health Centre in collaboration with the St George Dermatology and Skin Cancer Clinic is undertaking a clinical trial examining the effect of immune milk proteins on atopic dermatitis. Atopic dermatitis, otherwise known as eczema, is an inflammatory skin condition. If you have mild to moderate eczema we are looking for you!

 

The study is a 12 week double blind placebo controlled parallel trial. The supplementation period runs for 8 weeks with a follow up appointment 4 weeks after finishing supplementation.

 

If you agree to participate you will be required to:

  • Consume a whey-derived supplement or placebo daily for 8 weeks;
  • Attend the St George Dermatology and Skin Cancer Centre every two weeks for 8 weeks (during supplementation) and four weeks (week 12) after finishing supplementation to

o   Have your eczema assessed by a dermatologist;

o   Complete a questionnaire; and

o    Provide a blood sample.

  • Provide a skin sample at week 0, week 8 and week 12 after finishing supplementation.

 

The benefits of being in the trial are that you will receive specialist treatment for your eczema and trial a natural product that is showing promise to reduce the severity of atopic eczema.

 

Study Title:                 As above

 

Chief Investigator:     Professor Allan Cripps / Associate Professor Stephen Shumack

 

Other Investigators: Professor Barbara Fazekas de st Groth, Dr Phillip Tong, Dr Nicholas West,

                                    Dr Amanda Cox, Ms Sharyn Hutchinson, Ms Suzanne Asad

 

Selection Criteria:       Inclusion criteria: diagnosis of atopic eczema, age 18-60

 

Any participant that:

  • is lactose intolerant
  • consumes fish oil, probiotics, prebiotics, whey protein supplements during the trial period
  • requires insulin use (for treatment of diabetes)has history of liver, kidney or thyroid disease
  • uses anti-inflammatory or immune-modulating medications
  • has heavy alcohol consumption
  • is pregnant or intends to become pregnant.

will be excluded from participation in the study, as these conditions may interfere with the study design objectives

to monitor inflammation and gene expression in response to supplementation.

 

Clinical Trial Sites:   St George Dermatology and Skin Cancer Centre,

Centenary Institute for Cancer Medicine and Cell Biology,

Royal Prince Alfred Hospital Sydney, Griffith University.

 

                           To find out more about this trial, or to volunteer, please contact:

 

             Ms Sharyn Hutchinson: [email protected] or (02) 95 874277

                                    Dr Nicholas West: [email protected] or 0421 627 367

 

Leave a Reply